BioMarin Enters Into Exclusive Worldwide License Agreement for Investigational Fabry Disease Therapy

BioMarin Pharmaceutical Inc. announced an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an investigational long-acting, subcutaneous enzyme replacement therapy for Fabry disease.

According to the announcement, BioMarin will make an upfront payment of $70 million. GC Biopharma and Hanmi Pharm will be jointly eligible to receive additional milestone payments and tiered royalties on net sales. Following the ongoing Phase 1/2 clinical trial, BioMarin will assume sole responsibility for subsequent clinical development, manufacturing, and commercialization outside of Korea, while GC and Hanmi retain commercialization rights in Korea.

Understanding Fabry Disease and HM15421/GC1134A

• Condition: Fabry disease is an inherited lysosomal storage disorder caused by genetic changes in the GLA gene, leading to reduced activity of the alpha-galactosidase A enzyme.
• Treatment Candidate: HM15421/GC1134A is designed to extend half-life and improve stability, allowing for subcutaneous dosing.
• Regulatory Status: The candidate received Orphan Drug Designation from the U.S. FDA in 2024 and is currently being evaluated in a Phase 1/2 clinical trial.

Practical Implications and Verification

The agreement expands BioMarin's portfolio in rare genetic conditions. Readers and investors can verify the details by reviewing official regulatory filings and press releases through BioMarin Pharmaceutical's investor relations website or SEC disclosures.